Objective To assess the outcomes in a large cohort of patients suffering from rheumatic diseases admitted to the ICU of a tertiary university medical center. Methods A retrospective chart analysis was performed in 108 patients suffering from various rheumatic diseases and the outcomes, including morbidity and mortality, were assessed in relation to the underlying diseases, treatments and complications. Results Overall, 48 patients with rheumatoid arthritis, five patients with spondyloarthritis, 14 patients with vasculitis, 30 patients with connective tissue diseases and 11 patients suffering from other rheumatologic conditions were admitted to the intensive care unit (ICU). The reasons for ICU admission included infection (30%), cardiovascular complications (22%), gastrointestinal problems (18%), endocrinological disorders (7%), neurological complications (2%) and others (3%). A total of 4% of the admitted patients required close monitoring and 14% suffered from acute exacerbation of the underlying rheumatic disease. The ICU mortality rate was 16%, whereas the overall hospital mortality rate was 20%. Fatal outcomes were related to exacerbation of the rheumatic disease in 14% of the patients, infectious complications in 46% of the patients and other reasons in 41% of the patients. An increased Apache II score, the need for mechanical ventilation, renal replacement therapy, treatment with vasopressor drugs and plasma exchange therapy were identified as risk factors for mortality. Conclusion The overall outcomes of critically ill patients with rheumatic diseases are impaired compared to that observed in other patient groups. However, there were no significant differences in outcomes between the different rheumatic disease groups or based on the use of immunosuppressive therapy in this study. An increased Apache II score, the need for mechanical ventilation, renal replacement therapy, treatment with vasopressor drugs and plasma exchange therapy were identified as risk factors for mortality.
Introduction
Due to the systemic nature of rheumatic diseases and the specific treatments employed, affected patients have a high risk of developing complications requiring intensive care treatment (1) . The mortality rate among critically ill patients with rheumatic diseases has been reported to be higher than that of the general ICU population, despite the relatively younger age of these patients (2) , with reported mortality rates of 30-50% in ICU-treated patients with rheumatic diseases, reaching up to 40-60% with respect to hospital mortality (3, 4) .
Differentiating between septic complications and acute flare ups of rheumatic disease is frequently challenging but very important for developing further therapeutic strategies and assessing outcomes. Therefore, the initiation or dose escalation of immunosuppressive drugs and/or anti-infective agents is essential. In addition, severe complications may result from complex medical treatments in such patients.
Despite the high frequency of ICU admissions, few data have been published on the prognosis and relevant prognostic factors in patients with rheumatic diseases. Some studies have suggested a close correlation between the Apache II score on admission and overall mortality in these patients (4) and identified opportunistic infections and/or septic complications as additional risk factors (2) . With regard to the underlying rheumatic disease, it has been demonstrated that critically ill patients suffering from systemic lupus erythematosus (SLE) exhibit similar 60-day survival rates to patients with other types of rheumatic diseases (5) . However, the significance and effects of different treatment modalities prior to the manifestation of complications requiring intensive care treatment on outcomes have not been determined. Therefore, the outcomes, including ICU and hospital mortality, of a cohort of critically ill patients suffering from various underlying rheumatic diseases were assessed and data for pre-existing treatment modalities, reasons for admission to the ICU, complications, organ failure and various treatment strategies were analyzed in a standardized fashion.
Materials and Methods

Patients
A retrospective chart analysis was performed among 108 patients with underlying rheumatic diseases admitted to the ICU of our tertiary medical center between January 1, 2003 and December 31, 2010. Specialized intensive care staff members treated all patients in cooperation with the attending rheumatologists.
Rheumatological diagnoses
The underlying rheumatic diseases included the following conditions: rheumatoid arthritis (RA), spondyloarthritis (reactive arthritis, psoriasis arthritis, ankylosing spondylitis i. e.), vasculitides, connective tissue diseases (systemic lupus erythematosus, systemic sclerosis, myositis, Sjögren's syndrome and mixed connective tissue diseases) and others (adult-onset Still's disease, antiphospholipid-antibody syndrome, macrophage-activating syndromes and the presence of more than one rheumatologic condition).
Reasons for admission
The reasons for admission were grouped into the following categories: exacerbation of the rheumatic disease, infectious complications, gastrointestinal disorders, cardiovascular complications, neurological and/or endocrinological conditions or the need for close monitoring (after surgery, while intoxicated and during a "fasting test" in one patient with a suspected insulinoma).
Laboratory parameters
Laboratory parameters were evaluated, including the white blood cell count and C-reactive protein (CRP) and procalcitonine (PCT) levels. The values on the day of admission were documented, as well as those obtained on days 2 and 4 after the start of ICU treatment.
Additional parameters
Additional parameters included the duration of ICU treatment, source of admission and secondary ICU treatments applied upon transfer to a peripheral ward. The first ICU treatment was evaluated in each patient, and a "do not resuscitate" status was documented. supporting therapies was documented, including vasopressors, non-invasive ventilation, invasive ventilation, renal replacement therapy and plasma exchange therapy. Moreover, the need for surgical procedures was assessed, and the Acute Physiology and Chronic Health Evaluation (APACHE) II Score (6), Simplified Acute Physiology Scale (SAPS) II Score (7) and Multiple Organ Dysfunction Score (MODS) (8) were calculated on ICU admission and included into the data analysis. Both ICU and hospital mortalities were documented.
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Statistical analysis
The SPSS 18.0 statistical software package (SPSS, Chicago, USA) and Microsoft Excel program were used for the statistical analyses. The values are presented as total numbers, the median and range or percentages, as applicable.
Correlations between mortality and the clinical items (APACHE II, SAPS II) were evaluated using the Chi-square test and Fisher's exact test, when applicable, and the MannWhitney U test was applied for nonparametric variables. ICU mortality was analyzed as a major outcome variable. In addition, differences in baseline characteristics were assessed with Pearson's chi-square test for categorical variables and the Mann-Whitney U test for nonparametric variables. A p value of <0.05 was considered to be statistically significant.
Results
Patient characteristics
The characteristics of all 108 patients included in this study are presented in Table 1 . Data for gender, length of ICU treatment and the APACHE II, SAPS II and MODS scores were collected, and the underlying rheumatic disease and reason for ICU admission were evaluated.
The patients were classified into five groups based on the underlying rheumatic disease, as follows: 48 patients with rheumatoid arthritis, five patients with spondyloarthritis, 14 patients with vasculitis, 30 patients with connective tissue diseases and 11 patients categorized as "others." For more details for each category, see Table 1 .
The reason for admission was classified into the following seven categories: exacerbation of the underlying rheumatic disease (31%); infectious complications (16%), including sepsis, pneumonia, infection with cytomegalovirus and endocarditis; gastrointestinal disorders (19%), including gastrointestinal bleeding, pancreatitis, acute liver failure; cardiovascular disorders (10%), including embolism of the lungs, myocardial infarction, reanimation and rhythm instability; endocrinological (6%) and neurological (3%) disorders, including seizures and paraesthesia. Five other patients (5%) were transferred to the ICU for monitoring.
Outcomes
The rate of ICU mortality was 16% (17 patients), with an overall hospital mortality rate of 20% (22 patients). A "donot-resuscitate-order" was documented during the time of the (ICU) treatment in 11 of the 22 patients with a fatal outcome.
An infectious complication leading to septic multi-organ failure with a fatal outcome was identified in 12 patients, while exacerbation of the underlying rheumatic disease was observed in four patients. Six patients died for other reasons (Table 2) .
Treatment modalities
In order to assess whether the treatment modality for rheumatic disease administered prior to ICU admission affects the outcome, the patients' therapies were evaluated. As indicated in Table 3 , prednisolone was used prior to ICU treatment in the majority of patients (n=76). Treatment with one conventional DMARD was applied in 51 patients, whereas six patients were treated with a combination of DMARDs. The use of biologics was documented in 11 patients, and treatment with cytostatic agents was recorded in 21 patients.
In addition, ICU-related treatment choices were analyzed, including non-invasive ventilation, mechanical ventilation, renal replacement therapy, vasopressor therapy and plasma exchange therapy. Regarding ventilation support, it was differentiated whether the patient required non-invasive, invasive or both types of respiratory support. Renal replacement therapy was initiated in 25 patients (23%) and plasma exchange therapy was administered in nine patients (8%). Overall, 44% of the patients received treatment with a vasopressor. The data are summarized in Table 4 .
Patient-related outcomes
With respect to patient-related outcomes, neither age nor gender had a significant effect on the outcome. In addition, neither the underlying rheumatic disease nor reason for admission predicted the patient's course (Table 5) . Regarding the ICU scores, only the Apache II score demonstrated a significant correlation with mortality.
Treatment-related outcomes
The ordinary Chi-square test and, where applicable, Fisher's exact test were utilized to evaluate the correlations between the treatment options and mortality. Consequently, no significant effects of preceding rheumatic treatment were observed on ICU mortality (Table 3 ). As to organ-supporting therapies, the patients requiring mechanical ventilation, renal replacement therapy, treatment with a vasopressor or plasma exchange therapy had poor outcomes (Table 4) .
Discussion
There are only few studies addressing the clinical aspects and prognostic features of patients suffering from rheumatic diseases who require intensive care treatment (3, 9-18). Therefore, we analyzed a cohort 108 patients with different underlying rheumatic diseases admitted to the ICU due to complications who received treatment in a standardized fashion. In line with previous reports, we observed ICU admission predominantly among patients suffering from RA and systemic rheumatic diseases, including vasculitides and connective tissue diseases. The majority of the patients were women, reflecting the female predominance of rheumatic diseases (19) . Compared to that observed in other studies, our findings showed better outcomes, with an ICU mortality rate of 16% and a hospital mortality rate of 20%, which may reflect the effects of recent advances in ICU management and rheumatologic care (3, (9) (10) (11) 13) . In addition, the median Apache II score was 12 among the admitted patients, which is lower than that noted in previous observa- ions (2, 5, 12) . The present results demonstrated a substantial impact of treatment for the underlying rheumatic disease prior to ICU admission on the outcomes of the patients. However, despite performing a careful analysis, no correlations were identified between the different treatments administered prior to ICU admission and the outcome. Although treatment with higher doses of corticosteroids has been implicated in the onset of infectious complications (20) , there were no findings indicating an increased risk of severe infection requiring ICU treatment for any of the prednisolone doses utilized in this study. In addition, the administration of corticosteroids at all doses was not found to be a risk factor for mortality, and previous treatment with DMARDs did not affect the outcomes of the admitted patients. However, there was a trend towards ICU admission among patients pre-treated with bi- ologics, a finding supported by the results of numerous register studies demonstrating an increased risk of various infections in patients treated with biological agents (21) . In addition, an increased risk of infection has also been attributed to treatment with DMARDs, including MTX, azathioprine, leflunomide and cyclosporine, depending on the dose and treatment period (22) . In line with these findings, we noted a trend towards a poor outcome in the subgroup of patients pre-treated with cytotoxic drugs among our cohort. Furthermore, the use of immunosuppressive drugs during ICU treatment, including prednisolone, and/or immunoglobulin did not influence mortality. However, the mortality rate was higher in the patients treated with hydrocortisone due to sepsis. Despite an ongoing debate and the lack of robust data, the application of hydrocortisone treatment in patients presenting with severe septic shock remains an accepted therapy (23) , indicating that the patients who received hydrocortisone in our cohort had a poor prognosis due to the severity of septic disease. The Apache II score is frequently used as a tool to predict the patient's outcome (6) . However, there are conflicting results regarding the significance of this scoring tool with respect to the outcomes of ICU patients. Although previous studies have demonstrated that the Apache II score is a suitable predictor of the outcomes in patients admitted to the ICU (9, 11, 13, 14, 17, 24, 25) , this observation has not been confirmed in other studies (3, 26) ; the latter studies reported that the Apache II score is not independently, or only weakly, associated with mortality. Therefore, we performed a careful analysis of the Apache II score, which subsequently demonstrated a strong correlation between an increased Apache II score and a poor outcome in our cohort, supporting the use of this tool in patients with rheumatic diseases admitted to the ICU. This observation is important, as patients suffering from rheumatic diseases represent only a minor group of ICU patients, who have not been adequately evaluated in validation studies of the Apache score. In addition, patients with rheumatic diseases admitted to the ICU are generally of a younger age than the majority of ICU patients, which may affect the clinical significance of this parameter.
The need for organ replacement therapy, such as that involving mechanical ventilation, the use of vasopressors or renal replacement therapy, has been documented in many ICU populations as predictors of a poor outcome. In line with these results, the use of these therapies was found to be associated with a significantly higher mortality in our cohort of patients. Remarkably, the need for mechanical ventilation, including non-invasive ventilation, was identified to be a critical predictor in our subjects, as 14 patients received non-invasive ventilation without requiring later intubation, in contrast to 42 patients (39%) who were intubated. This rate is comparably lower than that reported in other case series (68-87%) (15, 26) , which may be due to the early use of non-invasive ventilation, a factor classically associated with a lower incidence of intubation in patients with hypoxemic respiratory failure, which has been reported in patients suffering from malignant diseases (27) (28) (29) . The use of renal replacement therapy results in higher mortality in ICU populations. This observation was confirmed by our results, although we did not assess whether the patients had preexisting renal dysfunction. In addition, the reason for renal impairment was not assessed due to the retrospective nature of the study design. Plasma separation is considered to be an important treatment strategy in critically ill patients with rheumatic diseases, as the administration of unselective plasma separation using other colloid substances (albumin or fresh frozen plasma), has the potential to remove immunoglobulin and immune complexes as well as proinflammatory cytokines. On order to enhance the treatment efficacy, multiple cycles must be performed, typically daily or every other day, for one to two weeks. Rapid progressive glomerulonephritis (RPGN), pulmonary hemorrhage mediated by anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides, Goodpasture syndrome, autoimmune hemolytic syndrome and hemolytic-uremic syndrome ( HUS ) / thrombotic-thrombocytopenic purpura (TTP) are usually treated with plasma exchange (30) . Nine patients (8%) in our cohort received plasma exchange therapy, a treatment that was found to be significantly associated with an in-creased mortality rate (p=0.014), supporting previous findings.
The present study is associated with several limitations. All data were derived from a cohort at a single tertiary hospital, which limits the applicability of our findings to the general rheumatic patient population. In addition, due to the retrospective nature of the study design, only a limited set of parameters were assessed. Furthermore, the study design did not allow for an analysis of the long-term outcome. Nevertheless, the present results identified clinically relevant parameters suitable for predicting the outcomes in critically ill patients with rheumatic diseases.
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